Under Eye Filler and Vision: the Anatomy, and What the First Hour Actually Requires

This is the risk nobody wants to read about and everybody should, because it is the only complication of under eye filler that is not reversible with time, patience or a second appointment. It is also the complication where the difference between a bad outcome and a catastrophic one is measured in minutes and depends almost entirely on preparation that happens before the needle goes anywhere near you.

Let us be precise about scale first. Vision loss after hyaluronic acid filler is rare. It is also not theoretical. A systematic review of the published literature collected cases across injection sites and product types and found the pattern consistent enough to describe clearly (Aesthetic Plastic Surgery, 2020). The under eye is one of the higher risk territories on the face for anatomic reasons that are worth understanding rather than glossing over.

The original element in this piece is a first hour escalation script, broken into three time windows, stating what to say and in what order, plus a two question preparedness check to run on a clinic before you book. Neither exists in patient facing form anywhere, which is remarkable for a complication whose entire management depends on speed.

The anatomy, briefly and without euphemism. The eye is supplied by the ophthalmic artery, a branch of the internal carotid. Several of its branches run forward out of the orbit and into the face, including the supratrochlear, supraorbital and dorsal nasal arteries around the inner corner of the eye, and the infraorbital artery below it. These are connections between the external facial circulation and the internal circulation of the eye, and they run in both directions.

That last point is the mechanism. If filler is injected into one of these vessels under enough pressure, it can travel backward against normal flow, into the ophthalmic artery, and then forward again into the central retinal artery, occluding it. The result is a central retinal artery occlusion, and it has been documented following facial hyaluronic acid injection in the ophthalmology literature (Archivos de la Sociedad Espanola de Oftalmologia, 2023). The retina tolerates ischemia poorly and briefly. That is why this is a minutes problem rather than an hours problem.

What it feels like. Almost universally immediate, meaning during the injection or within seconds to minutes of it. Sudden severe pain in or around the eye, often described as unlike ordinary injection discomfort. Sudden visual change in one eye, which may be complete loss, a curtain, a dark central patch, or blurring. Frequently nausea and sometimes a headache. Skin changes in a vascular pattern, meaning mottled violaceous discoloration, may appear at the same time or shortly afterward. What it is not is a symptom that emerges the next morning. Delayed visual symptoms have other explanations, most of them benign, though they still merit a call.

The first hour script, window one, zero to five minutes. Say the words out loud, immediately, without softening them: my vision has changed in my left eye, this started during the injection. Ask the injector to stop and to note the exact time, the exact product and the exact volume already placed. Do not leave the chair and do not go home to see if it settles. The single most common failure mode described in case reports is delay caused by the patient not wanting to overreact and the injector wanting to observe for a few minutes.

Window two, five to twenty minutes. This is the window in which management is attempted. Published management centers on hyaluronidase, the enzyme that degrades hyaluronic acid, delivered in and around the affected territory, with retrobulbar administration described in the literature as an attempted rescue. It is important to be honest about how strong that evidence is. A 2024 systematic review of administration method and potential efficacy of hyaluronidase for filler related vision loss found the evidence limited and outcomes inconsistent rather than reliably restorative (Aesthetic Plastic Surgery, 2024). That is not a reason to skip it. It is a reason not to believe that a clinic having hyaluronidase on the shelf makes this a solved problem.

Your job in this window is to make sure two things are happening in parallel rather than in sequence: the injector is managing, and someone is arranging emergency ophthalmology. Ask directly, who is calling ophthalmology right now.

Window three, twenty to sixty minutes. You should be en route to or arriving at an emergency department with ophthalmology cover, not a general urgent care. The phrase that gets you triaged correctly is suspected filler related retinal artery occlusion, and it is worth saying exactly that at reception rather than describing it as a bad reaction to a cosmetic injection. Bring or photograph the product box and lot number, the volume, the injection sites, and the time of onset. Case reports repeatedly note incomplete documentation as an obstacle to management (Annals of Plastic Surgery, 2021).

The two question preparedness check, to run before you book. First: what is your protocol if a patient reports visual change during an under eye injection, and where is the nearest emergency department with ophthalmology cover. You are not testing whether they have hyaluronidase. Everyone says yes to that. You are testing whether an actual pathway exists, with a named destination. A clinic that has thought about this answers in about ten seconds. A clinic that has not will improvise, and you will hear it.

Second: do you inject the under eye with a needle or a cannula, and why. There is no universally correct answer and the tradeoffs are genuinely debated, which is the subject of cannula vs needle for the tear trough. What you are listening for is a reasoned answer about vessel avoidance rather than a preference stated as a fact.

What the studies do not tell you. There is no reliable denominator. Because filler treatments are not centrally registered and adverse events are reported inconsistently, every incidence figure quoted for filler related blindness is an estimate built on case collection rather than on a known number of treatments. That cuts both ways. It means the true rate could be lower than the figures circulating, and it means nobody can tell you your personal risk with any precision. There is also no randomized evidence for any rescue protocol, and there never will be, because the event is too rare and too urgent to randomize. Management rests on mechanism and on case series.

None of this is an argument against having under eye filler. It is an argument for treating injector selection as a safety decision rather than an aesthetic one, which is the point of choosing an injector for under eyes, and for reading the full risk picture in under eye filler risks to understand before your first appointment rather than after it.

One last practical note. Because hyaluronidase is central to managing both this and the far more common non vascular problems, ask whether the clinic stocks it in date and in adequate quantity, not merely whether they have some. The reasons you might need it for entirely non urgent reasons are covered in when to dissolve under eye filler. A clinic that keeps a single small vial for cosmetic corrections is not equipped for an emergency, and that is a question you can ask pleasantly, once, before you ever sit down.